SCHEDULE 13G: Medicxi Entities Disclose Significant 16.9% Stake in RAPT Therapeutics

Medicxi IV LP, Medicxi Co-Invest IV LP, and their related entities have disclosed a combined beneficial ownership of 16.9% of RAPT Therapeutics, Inc.'s common stock.

Summary

• Medicxi IV LP, Medicxi Co-Invest IV LP, Medicxi IV GP Limited, and Medicxi Ventures Management (Jersey) Limited have filed a Schedule 13G, disclosing their beneficial ownership in RAPT Therapeutics, Inc.
• As of December 27, 2024, Medicxi IV LP directly owns 21,977,977 shares, representing approximately 16.6% of the outstanding common stock.
• Medicxi Co-Invest IV LP directly owns 374,023 shares, representing approximately 0.3% of the outstanding common stock.
• Collectively, Medicxi IV GP Limited and Medicxi Ventures Management (Jersey) Limited are deemed to beneficially own 22,352,000 shares, which accounts for approximately 16.9% of RAPT Therapeutics' outstanding common stock.
• The reported percentages are based on 132,006,828 shares of Common Stock outstanding as of December 27, 2024.
• All reporting persons are organized under the laws of Jersey and maintain their principal business office in St. Helier, Jersey.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

NA

Management Comments

• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing is a standard disclosure of a significant ownership stake by an institutional investor in a publicly traded biotechnology company, providing transparency regarding major shareholders.

Stakeholder Impact

• Shareholders gain transparency regarding a significant institutional investor's stake in the company, which can influence market perception and trading activity.

Key Dates

Keywords

RAPT Therapeutics, Medicxi, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Institutional Investor, Biotechnology